Research programme: cytokine inhibition - King's College London
Alternative Names: Cytokine inhibition research programme - King's College LondonLatest Information Update: 30 Aug 2002
Price :
$50 *
At a glance
- Originator Nonindustrial source
- Class
- Mechanism of Action Interleukin 5 inhibitors; Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Asthma; Rheumatoid arthritis
Most Recent Events
- 23 Jul 1999 Preclinical development for Asthma in United Kingdom (Unknown route)
- 23 Jul 1999 Preclinical development for Rheumatoid arthritis in United Kingdom (Unknown route)